About Enlaza Therapeutics
Enlaza Therapeutics is pioneering the field of covalent biologics — a novel class of protein therapeutics designed to deliver more efficacious and safer treatments for patients. The company's proprietary War-Lock™ platform uses synthetic biology to engineer proteins that form irreversible covalent bonds with disease-relevant targets. Enlaza is building a pipeline of first-in-class covalent biologics with an initial focus on oncology.
Company details
Funding
Total raised
$176M
Last stage
Series A
Investors
Founders
Sergio Duron
Ph.D. in organic chemistry from the University of Illinois at Urbana-Champaign. Managing Partner at Avalon BioVentures. Previously CSO and co-founder at Nerio Therapeutics (acquired by Boehringer Ingelheim), Calporta Therapeutics (acquired by Merck), and other Avalon portfolio companies.
LinkedInSanford (Sandy) Madigan
Ph.D. in Genetics from SUNY Stony Brook. Managing Partner at Avalon BioVentures. Previously co-founder and CEO of Nerio Therapeutics (acquired by Boehringer Ingelheim for up to $1.3B) and transacting CEO of Calporta Therapeutics (acquired by Merck for up to $576M).
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.